SCHEDULE: Great Point Partners Maintains 5.22% Stake in Context Therapeutics
Beneficial Ownership Report
Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a continued beneficial ownership of 5.22% in Context Therapeutics Inc. common stock.
Summary
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 4,683,711 shares of Context Therapeutics Inc. Common Stock.
- This ownership represents 5.22% of the company's outstanding common stock, based on 89,704,194 shares reported by Context Therapeutics Inc. in its Form 10-Q filed on May 7, 2025.
- The shares are held by Biomedical Value Fund, L.P. (3,138,086 shares) and Biomedical Offshore Value Fund, Ltd. (1,545,625 shares), for which Great Point Partners, LLC serves as the investment manager.
- Dr. Jeffrey R. Jay, as Senior Managing Member, and Ms. Lillian Nordahl, as Managing Director of Great Point Partners, LLC, possess shared voting and dispositive power over all 4,683,711 shares.
- The reporting persons disclaim beneficial ownership of the shares except to the extent of their respective pecuniary interests.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or operations.
Industry Context
This Schedule 13G filing is a routine disclosure of a significant ownership stake by an investment firm in a publicly traded biotechnology company. Such filings provide transparency into institutional holdings, which is a standard practice in the financial industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, confirming the continued interest of Great Point Partners, LLC.
Key Dates
| Date | Description |
|---|---|
| 2025-05-07 | Date Context Therapeutics Inc. filed its Form 10-Q, reporting 89,704,194 shares outstanding. |
| 2025-06-30 | Date of event requiring the filing of this statement. |
| 2025-08-14 | Date of the Joint Filing Agreement and the filing date of this Schedule 13G/A Amendment No. 4. |
Keywords
Context Therapeutics, Great Point Partners, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.